Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1614 | Decrease, androgen receptor activation |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1793 | Activator protein 1 activation |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.2 | KE:26 | Antagonism, Androgen receptor |
AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.33 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.4 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical Disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.